Unlike his father, David might stay active deep into his retirement years-if his current company, Unity Biotechnology, turns out to a success.
Unity is a Bay Area-based company developing drugs to treat specific diseases that accompany aging, where David is cofounder and president, This past fall, the company announced $116 million in Series B funding from some big names, including Venrock, ARCH Venture Partners, and Jeff Bezos’ venture fund Bezos Expeditions.
Unity is the best bet among the growing number of companies taking aim at aging to actually get a drug to market.
Deming’s enthusiasm is backed by money she invested through The Longevity Fund; she thinks Unity is the best bet among the growing number of companies taking aim at aging to actually get a drug to market.
Anyway, David bristles at the idea that Unity is an “Anti-aging” company. David expects Unity to test its first drug, for osteoarthritis of the knee, in humans within 18 months.
David says Unity’s has been shown to grow new cartilage in knees treated in a lab dish-a tantalizing first step toward maybe reversing osteoarthritis in humans.